Patents Assigned to Fornix Biosciences N.V.
  • Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNs) in a tissue, its selection, pharmaceutical compositions and use
    Patent number: 7410806
    Abstract: The invention relates to a compound suitable for inhibiting the influx of polymorphonuclear leukocytes (PMNs) into a tissue involved in a chronic inflammatory disease. The compound according to the invention is capable of forming a complex with N-acetyl-Pro-Gly-Pro. The invention also relates to a method of selecting such a compound, a pharmaceutical composition and an application of the compound.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: August 12, 2008
    Assignee: Fornix Biosciences N.V.
    Inventors: Franciscus Petrus Nijkamp, Rosswell Robert Pfister, Jeffrey Lynn Haddox, James Edwin Blalock, Matteo Villain
  • Vectors for enhanced expression of VEGF for atrial disease treatment
    Patent number: 7223740
    Abstract: The invention provides a vector which is capable of the expression of a vascular endothelial growth factor wherein the vector comprises a modified PCMV promoter. The invention further provides use of a vector which is capable of and expressing a vascular endothelial growth factor (VEGF) for the regulation of endothelial function, angiogenesis and arteriogenesis. The invention further comprises use of a vector which is capable of the expression of a vascular endothelial growth factor (VEGF) for the prophylactic treatment of arterial diseases and/or bone marrow diseases and/or neural diseases.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: May 29, 2007
    Assignee: Fornix Biosciences N.V.
    Inventors: Tjerk Johannes A. Visser, Folkert Feiko Roossien, Carola Jacoba M. Ubink-Bontekoe
  • Inhibition of protein binding to mast cells
    Patent number: 7056511
    Abstract: The invention relates to a compound inhibiting the binding of the free light chain of immunoglobulin (Ig LC) to mast cells. It has been found that Ig LC is the agent responsible for the sensitization of mast cells. The compounds according to the invention can thus be used for the preparation of a drug for the treatment of a disease whose symptom is an elevated Ig LC concentration in serum or spinal fluid. The invention also relates to a method of screening a series of compounds on their ability to reduce the sensitization of mast cells.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: June 6, 2006
    Assignee: Fornix Biosciences N.V.
    Inventors: Franciscus Antonius M. Redegeld, Aletta Desireé Kraneveld, Franciscus Petrus Nijkamp
  • Compound for inhibiting the influx of polymorphonuclear leukocytes (PMNS) in a tissue, its selection, pharmaceutical compositions and use
    Patent number: 6960565
    Abstract: The invention relates to a compound suitable for inhibiting the influx of polymorphonuclear leukocytes (PMNs) into a tissue involved in a chronic inflammatory disease. The compound according to the invention is capable of forming a complex with N-acetyl-Pro-Gly-Pro. The invention also relates to a method of selecting such a compound, a pharmaceutical composition and an application of the compound.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: November 1, 2005
    Assignee: Fornix Biosciences N.V.
    Inventors: Franciscus Petrus Nijkamp, Rosswell Robert Pfister, Jeffrey Lynn Haddox, James Edwin Blalock, Matteo Villain
  • Synthetic complementary peptides and ophthalmologic uses thereof
    Patent number: 6762166
    Abstract: The present invention is directed to a series of complementary peptides for the pro-gly-pro sequence as antagonists of polymorphonuclear leukocyte chemoattractants. Also provided are applications of such peptides for treating alkali-injuried eyes and other types of diseases.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: July 13, 2004
    Assignee: Fornix Biosciences N.V.
    Inventors: Jeffrey Lynn Haddox, Roswell Robert Pfister, James Edwin Blalock, Matteo Villain
  • Synthetic complementary peptides and ophthalmologic uses thereof
    Patent number: 6310041
    Abstract: The present invention is directed to a series of complementary peptides for the pro-gly-pro sequence as antagonists of polymorphonuclear leukocyte chemoattractants. Also provided are applications of such peptides for treating alkali-injuried eyes and other types of diseases.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: October 30, 2001
    Assignee: Fornix Biosciences N.V.
    Inventors: Jeffrey Lynn Haddox, Roswell Robert Pfister, James Edwin Blalock, Matteo Villain